What is the recommended management for a renal infarction?

Management of Renal Infarction

The primary management of renal infarction involves anticoagulation with heparin followed by warfarin for cardioembolic causes, antiplatelet therapy for arterial disease, and aggressive investigation of the underlying etiology to guide secondary prevention.

Initial Diagnostic Approach

The diagnosis of renal infarction requires a high index of suspicion, as it is frequently missed initially 1, 2. Key clinical features include:

• Classic triad: Flank/abdominal/lower back pain + elevated lactate dehydrogenase (LDH) + hematuria in patients with thromboembolic risk factors 1, 2
• Laboratory findings: Elevated serum LDH (present in 94-100% within 24 hours), hematuria (71-100% of cases), and leukocytosis 1, 2
• Imaging: Contrast-enhanced CT is the diagnostic modality of choice, showing wedge-shaped perfusion defects 3, 1

Etiological Investigation

Comprehensive etiological assessment is essential as it directly determines the antithrombotic strategy 4, 3:

• Cardioembolic causes account for approximately 56% of cases, with atrial fibrillation being the most common (present in 11/17 patients in one series) 3, 1
• Renal artery disease (atherosclerotic or traumatic injury) accounts for 7.5% 3
• Hypercoagulable states account for 6.6% 3
• Idiopathic causes represent 30% of cases 3

Invasive endovascular investigation with renal arteriography and intravascular ultrasound (IVUS) should be considered, as it identifies local arterial disease in 56% of patients, changes the diagnosis in 36%, and modifies antithrombotic strategy in 56% of cases 4.

Acute Antithrombotic Management

The antithrombotic approach depends on the underlying etiology 4, 3:

For Cardioembolic Sources:

• Initiate intravenous unfractionated heparin or low-molecular-weight heparin (enoxaparin preferred) immediately upon diagnosis 3
• Transition to warfarin for long-term anticoagulation 3
• This approach follows established principles for systemic embolization, similar to management of other embolic events 5

For Arterial Disease (Atherosclerotic RAS or Dissection):

• Antiplatelet therapy is reasonable when arterial pathology is identified 5, 4
• Following invasive investigation showing arterial disease, antiplatelet prescription increased significantly 4

Thrombolytic Therapy:

• Urokinase or other thrombolytics have been used in select cases (19/438 patients in one series) 3
• Evidence for benefit is limited, with one case report showing no functional recovery despite intra-arterial urokinase 2
• Consider only in cases of bilateral involvement or solitary kidney with acute presentation

Blood Pressure Management

Aggressive blood pressure control is critical, particularly in cases presenting with acute hypertension 6:

• Patients with acute hypertension associated with renal infarction may develop malignant hypertension and have markedly elevated plasma renin 6
• Blood pressure outcomes are favorable with intervention and/or medication, with mean BP decreasing from 183/111 to 127/80 mmHg in acute hypertension cases 6
• ACE inhibitors are recommended once hemodynamically stable, particularly in patients with evidence of renal dysfunction 5
• Some patients with acute hypertension may achieve normal blood pressure without treatment following recovery 6

Renal Function Preservation

Despite aggressive treatment, renal outcomes vary 3, 6:

• 20.1% develop acute kidney injury (AKI) during initial hospitalization 3
• 10.9% develop new-onset eGFR <60 mL/min/1.73m² 3
• 2.1% progress to end-stage renal disease (ESRD) requiring dialysis 3
• Long-term follow-up shows most patients maintain stable renal function if unilateral involvement 6, 2

Adequate hydration should be encouraged to support renal perfusion 5.

Revascularization Considerations

Endovascular revascularization is not routinely indicated for established renal infarction 5:

• Prospective trials in atherosclerotic RAS showed no superiority of renal artery stenting over optimal medical therapy for BP control, cardiovascular events, or mortality 5
• Consider revascularization only in specific circumstances: bilateral RAS with flash pulmonary edema, rapidly progressive treatment-resistant hypertension, or rapidly declining renal function in viable kidney (>8 cm length, distinct cortex >0.5 cm, resistance index <0.8) 5

Secondary Prevention

Long-term antithrombotic therapy is essential 4, 3:

• For cardioembolic etiology: Continue warfarin indefinitely (330/438 patients in one series) 3
• For arterial disease: Antiplatelet agents (157/438 patients) 3
• Dual antiplatelet therapy (DAPT) for at least 1 month if renal artery stenting is performed 5

Address cardiovascular risk factors aggressively 5:

• High-intensity statin therapy 5
• Beta-blockers if heart failure or reduced ejection fraction 5
• Smoking cessation 5

Prognosis and Follow-Up

Mortality during initial hospitalization is 5%, with 2.8% recurrence rate during median 20-month follow-up 3. Regular monitoring should include:

• Serial creatinine and eGFR measurements
• Blood pressure monitoring (office and ambulatory/home BP) 5
• Renal artery duplex ultrasound for surveillance 5
• Assessment for recurrent thromboembolic events

Common pitfall: The diagnosis is frequently delayed (24 hours to 6 days from admission) because initial working diagnoses include renal colic, pyelonephritis, or acute abdomen 2. Maintain high suspicion in any patient with flank pain and thromboembolic risk factors.